Clinical Trials Browser

Phase 3 × Completed × Crizotinib × Clear all

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

303 enrolled 31 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT01639001 2020-12-08

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Phase 3 Completed

207 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT00932893 2017-01-02

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Phase 3 Completed

347 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung